Now there is a question here, the Bharat Biotech made Covaxin has gotten its approval as a backup vaccine, Covaxin a backup vaccine? Also, the clinic trial on this vaccine hasn’t yet been completed, so this raises another question whether this vaccine can be directly used on COVID patients?
Walking through the reality first, the year 2020 saw the most terrifying and destructive situation in the areas of healthcare and economy due to the novel coronavirus. But this New Year has started out with some good news which we were hoping to hear earlier in 2020.
The Drugs Controller General of India, starting the limited emergency use of the two new vaccines, Covishield and Covaxin has been a satisfying news to the entire country.
Let’s take a look at the difference between the two vaccines:
Let’s first learn about the vaccine Covishield, on 3rd January Drugs Controller General of India approved for the emergency use of the Covishield and Covaxin in the country. In order to make Covishield, Pune’s Serum Institute of India has worked with Global Pharma Company, AstraZeneca and Oxford University.
On the other hand Bharat Biotech, with Indian Council of Medical Research and with assistance from the National Institute of Virology, have created the vaccine Covaxin.
On the approval of these vaccines, Pune’s Serum Institute of India’s CEO Adar Poonawala tweeted that all the risks and efforts taken by the Serum Institute in creating the vaccine has gotten positive feedback that this is safe and effective and ready for roll out.
Oxford AstraZeneca vaccine has shown a significantly positive response in comparison with other previous vaccines from 90-95% more effective, and at the same time being affordable and easy to store.
The answer to: why Covaxin a backup vaccine?
Hyderabad’s company Bharat Biotech with ICMR and National Institute of Virology has developed this vaccine. This is the first Indian made vaccine which is still under trial and only the animal trial and phase III data is available.
If the data of phase I & II trials are good, then why is Covaxin a backup vaccine? The director of All Indian Institute of Medical Sciences, Randeep Guleria, in an interview with The Quint stated that: Until Bharat Biotech does not complete the Phase III trials and the efficacy isn’t identified, Covishield will be the go-to vaccine for India.
The Bharat Biotech has done its Phase 1 & 2 trials on 800 subjects, in which they have found that this vaccine gives good immune response. The Phase III Efficacy trials has been started on 25,800 volunteers out of which 22,500 have received the vaccine.
According to Drugs Controller General of India, the data till now shows that the vaccine is safe to be used.
The trials of Covishield are also going on in India, but the data is also a collected information from other countries and according to that data, the efficacy of this vaccine is 70.4%.